Effects of Pioglitazone in Calcific Aortic Valve Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.
Also called NCT05875675
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 100 participants
- Registry
-
NCT05875675
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT05875675. Randomized; double masking; primary purpose prevention. Start 2023-07-01 (anticipated); primary completion 2025-07-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Pioglitazone in Calcific Aortic Valve Disease
- Condition
- Calcification of Aortic Valve
- Condition
- Aortic Valve Stenosis
- Intervention (Drug)
- Drug: Pioglitazone Oral Tablet
- Intervention (Dietary supplement)
- Placebo
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Record details
- Record id
cardio:ct-nct05875675- Content hash
f52231c8760290f649980f65ed0f55514ba103c432a6f69ef6a3c152a0d0e33f